TG Therapeutics Inc (TGTX)

Return on assets (ROA)

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Net income (ttm)	US$ in thousands	-14,364	95,686	41,197	12,672	-25,906	-175,654	-168,554	-198,335	-238,679	-288,498	-326,485	-348,100	-342,980	-344,506	-318,893	-279,381	-230,734	-205,501	-188,830	-172,870
Total assets	US$ in thousands	586,014	401,207	373,323	329,587	331,067	220,854	197,358	193,572	217,891	251,666	303,028	379,629	409,687	481,400	548,699	625,642	273,856	294,621	101,849	163,014
ROA		-2.45%	23.85%	11.04%	3.84%	-7.83%	-79.53%	-85.41%	-102.46%	-109.54%	-114.64%	-107.74%	-91.69%	-83.72%	-71.56%	-58.12%	-44.66%	-84.25%	-69.75%	-185.40%	-106.05%

September 30, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $-14,364K ÷ $586,014K
= -2.45%

The return on assets (ROA) for TG Therapeutics Inc has shown varying trends over the past few quarters. In the most recent quarter, as of September 30, 2024, the ROA was -2.45%, indicating a negative return on the company's assets. Prior to this, there was a significant increase in ROA to 23.85% as of June 30, 2024, which suggests improved efficiency in generating earnings relative to the company's assets.

Looking back further, the ROA gradually decreased from positive to negative values, reaching its lowest point at -185.40% as of March 31, 2020. This trend implies that the company may have been experiencing challenges in utilizing its assets effectively to generate profits during that period.

It is important to further analyze the underlying factors contributing to these fluctuations in ROA to gain a deeper understanding of the company's financial performance and efficiency in asset utilization.